Urgent need for more research into environmental effects of microplastics Additional solutions are urgently needed to limit emissions of microplastics into the environment. Growing quantities of microplastics (particles of 5 mm or less) are entering our living environment every day.
Circular economy: plastics recycling from end-of-life vehicles could be four times higher At present, 85% of plastics from end-of-life vehicles is still incinerated. Only 15% of plastics is reused as a raw material. A survey conducted by RIVM has revealed possibilities to expand recovery of these plastics fourfold by 2030.
Proposed European PFAS ban officially submitted The Netherlands, Germany, Denmark, Sweden and Norway today took the first formal step towards a European ban on per- and polyfluoroalkyl substances (PFAS) by jointly submitting a restriction proposal to the European Chemicals Agency (ECHA).
More than two million invitations to get vaccinated against HPV in 2023 In early 2023, 1.3 million young adults will receive an invitation to get vaccinated against the human papillomavirus (HPV). This group comprises around 900,000 men and 400,000 women between the ages of 19 and 27.
Changed indicative magnetic field zones around overhead high-voltage lines RIVM has updated the 2005 grid map (Netkaart) showing the overhead high-voltage lines in the Netherlands.
INHERIT Model: a tool to jointly improve health, environmental sustainability and Health Equity RIVM is involved in the Horizon2020 project INHERIT. The first article of the INHERIT project has been published, lead-authored by RIVM.
RIVM on shortlist Best Government Organisation of the Year 2018 The National Institute for Public Health and the Environment (RIVM) has made the shortlist for the 2018 election for best government organisation of the year.
RIVM supports WHO in national capacity building for measuring foodborne disease burden RIVM’s Collaborating Centre for Risk Assessment of Pathogens in Food and Water was invited to WHO’s side event during the 41st Codex Alimentarius Commission on July 4th 2018.
Rapid developments in modern biotechnology are a challenge for risk assessment Due to developments in modern biotechnology, such as genome editing, synthetic biology and regulation of gene expression, many new applications are expected in the next ten years.
Meningococcal disease serious, but still rare Meningococcal disease is a disease caused by a bacterium, the meningococcus. There are several types of this bacterium. In most cases, it does not make you ill.